Evidence map›Paper›PMID 36793051›Full record

ArticleAnnals of clinical microbiology and antimicrobials2023

Persistent bacteremia predicts poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections receiving appropriate therapy.

Abi Manesh Sathya Kumar, Mithun Mohan George, Kundakarla Bhanuprasad, Grace Mary John, Anu Korula, Aby Abraham, Vikram Mathews, Uday Prakash Kulkarni, Chaitra Shankar, Prasanna Samuel Premkumar and 5 more

Abstract read
In one paragraph

Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. JAC-antimicrobial resistance · 2024
    Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Abi Manesh Sathya KumarDepartment of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.
Mithun Mohan GeorgeDepartment of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.
Kundakarla BhanuprasadDepartment of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.
Grace Mary JohnDepartment of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.
Anu KorulaDepartment of Hematology, Christian Medical College, Vellore, Tamil Nadu, India.
Aby AbrahamDepartment of Hematology, Christian Medical College, Vellore, Tamil Nadu, India.
Vikram MathewsDepartment of Hematology, Christian Medical College, Vellore, Tamil Nadu, India.
Uday Prakash KulkarniDepartment of Hematology, Christian Medical College, Vellore, Tamil Nadu, India.
Chaitra ShankarDepartment of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.
Prasanna Samuel PremkumarDepartment of Biostatistics, Christian Medical College, Vellore, Tamil Nadu, India.
Binila ChackoDivision of Critical Care, Christian Medical College, Vellore, Tamil Nadu, India.
K SubramaniDivision of Critical Care, Christian Medical College, Vellore, Tamil Nadu, India.
George M VargheseDepartment of Infectious Diseases, Christian Medical College, Vellore, Tamil Nadu, India.
V BalajiDepartment of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.
Biju GeorgeDepartment of Hematology, Christian Medical College, Vellore, Tamil Nadu, India. biju@cmcvellore.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIdentifying persistent bacteremia early in patients with neutropenia may improve outcome. This study evaluated the role of follow-up blood cultures (FUBC) positivity in predicting outcomes among patients with neutropenia and carbapenem-resistant gram-negative bloodstream infections (CRGNBSI).

methodsThis retrospective cohort study conducted between December 2017 and April 2022 included patients more than 15 years old with neutropenia and CRGNBSI, who survived for ≥ 48 h, receiving appropriate antibiotic therapy and had FUBCs. Patients with polymicrobial bacteremia within 30 days were excluded. The primary outcome was 30 day mortality. Persistent bacteremia, septic shock, recovery from neutropenia, prolonged or profound neutropenia, requirement of intensive care and dialysis, and initiation of appropriate empirical therapy were also studied.

resultsIn our study cohort of 155 patients, the 30 day mortality rate was 47.7%. Persistent bacteremia was common in our patient cohort (43.8%). Carbapenem resistant isolates identified in the study were K.pneumoniae (80%), E.coli (12.26%), P.aeruginosa (5.16%), A.baumanii (1.94%) and E.cloacae (0.65%). The median time for sending a FUBC was 2 days (IQR, 1-3 days). Patients with persistent bacteremia had higher mortality than those without (56.76% versus 32.1%; p < 0.001). Appropriate initial empirical therapy was given to 70.9%. Recovery from neutropenia occurred in 57.4% while 25.8% had prolonged or profound neutropenia. Sixty-nine percent (107/155) had septic shock and needed intensive care; 12.2% of patients required dialysis. Non-recovery from neutropenia (aHR, 4.28; 95% CI 2.53-7.23), presence of septic shock (aHR, 4.42; 95%CI 1.47-13.28), requirement of intensive care (aHR,3.12;95%CI 1.23-7.93), and persistent bacteremia (aHR,1.74; 95%CI 1.05-2.89) significantly predicted poor outcomes in multivariable analysis.

conclusionFUBC showing persistent bacteremia predicted poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections (CRGNBSI) and should be routinely reported.

Indexed as

BacteremiaNeutropeniaShock, SepticAdolescentAnti-Bacterial AgentsCarbapenemsHumansRetrospective StudiesAnti-Bacterial AgentsCarbapenemsBloodstream infectionsCarbapenem resistanceNeutropeniaPersistent bacteremia

Identifiers

PMID36793051
PMCPMC9933361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.